Pharmacovigilance of semaglutide: A descriptive analysis of WHO-VigiAccess reports. [PDF]
Medicine (Baltimore)Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is widely prescribed for type 2 diabetes mellitus and chronic weight management. With its growing global use, continuous pharmacovigilance is essential to detect emerging patterns of adverse drug reactions (ADRs).
Alorfi NM +9 more
europepmc +2 more sources
Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real-World Analysis of WHO Pharmacovigilance Data. [PDF]
Clin Pharmacol TherBRAF inhibitors and MEK inhibitors (MEKi) have reshaped the treatment of BRAFV600‐mutant malignancies; however, cutaneous adverse drug reactions (ADRs) remain a frequent and clinically impactful toxicity. Although clinical trials provide insight into their safety profiles, real‐world data on dermatologic ADRs are limited.
Sauer N +3 more
europepmc +2 more sources
Correction: Comparative real-world safety profiles of caspofungin, micafungin, and anidulafungin: a disproportionality analysis based on FAERS and VigiAccess databases [PDF]
Frontiers in PharmacologyJingxiu Chen +8 more
doaj +2 more sources
Real‑world safety evaluation of tranexamic acid: Signal detection from FAERS and VigiAccess databases. [PDF]
PLoS OneBackground Tranexamic acid (TXA) is an antifibrinolytic agent commonly used to mitigate blood loss across various medical indications. Despite its widespread use, comprehensive data on its safety profile remain limited. This study aimed to systematically evaluate adverse events (AEs) associated with TXA.
Feng J, Guo C, Zhao S.
europepmc +2 more sources
A severe case of rhabdomyolysis after Moderna mRNA anti‐COVID‐19 vaccine with a literature review
Clinical Case Reports, Volume 11, Issue 5, May 2023., 2023 The identification of rhabdomyolysis as a potential fatal adverse reaction to recent COVID‐19 vaccines is essential. As the symptoms of rhabdomyolysis are not specific, the threshold to actively search for this complication should be low. Abstract The identification of rhabdomyolysis as a potential fatal adverse reaction to recent COVID‐19 vaccines is ...
Maria Sheka +3 more
wiley +1 more source
Adverse Reactions of First-Line Tyrosine Kinase Inhibitors in Advanced Hepatocellular Carcinoma Treatment: A Descriptive Analysis From WHO-VigiAccess. [PDF]
Int J HepatolAims: To determine the safety of first‐line tyrosine kinase inhibitors (TKIs) in advanced hepatocellular carcinoma (HCC) treatment by assessing the adverse drug reactions (ADRs) as reported in the World Health Organization (WHO)–VigiAccess database.
Sui WF +5 more
europepmc +2 more sources
The risk of worsening of myasthenia by cardiovascular medication as reflected by reporting frequency
European Journal of Neurology, Volume 28, Issue 9, Page 2965-2970, September 2021., 2021 From counts of adverse drug reaction reports from databases, the reporting odds ratio can be calculated and serve as a surrogate for the risk of myasthenia worsening due to drugs commonly used in cardiovascular diseases. An increased risk of beta‐blockers and calcium antagonists is confirmed with this method.
Peter Trillenberg +3 more
wiley +1 more source
European Journal of Neurology, Volume 28, Issue 7, Page 2349-2356, July 2021., 2021 Entries in databases of adverse drug reactions can be used to compare the risk of myasthenia worsening due to drugs. We determined a quantitative surrogate (reporting odds ratio [ROR]) for antiepileptic, antidepressant, neuroleptic, and sedative drugs. Although the ROR was increased for some drugs, their ROR was always smaller than for atorvastatin, a ...
Peter Trillenberg +3 more
wiley +1 more source
Safety profile of camrelizumab: An analysis based on literature and database review. [PDF]
PLoS OneObjective Real-world studies on the safety of camrelizumab are scarce. This study aimed to investigate the adverse drug reactions (ADRs) associated with camrelizumab and evaluate their clinical characteristics and
Huang Y, Li W.
europepmc +2 more sources